Non-small cell lung cancer, MET-mutated
Jump to navigation
Jump to search
| Page editor | Section editor | ||
|---|---|---|---|
 |
Eric K. Singhi, MD MD Anderson Cancer Center Houston, TX, USA |
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO
- 2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline PubMed
ESMO
- 2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Non-Small Cell Lung Cancer.
Metastatic disease, all lines of therapy
Capmatinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Wolf et al. 2020 (GEOMETRY mono-1) | 2015-NR | Phase 2 (RT) |
Biomarker eligibility criteria
- MET exon 14 skipping alterations
Targeted therapy
- Capmatinib (Tabrecta) 400 mg PO twice per day on days 1 to 28, taken with or without food
28-day cycles
References
- GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains dosing details in abstract PubMed NCT02414139
Tepotinib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Paik et al. 2020 (VISIONNSCLC) | 2016-2020 | Phase 2 (RT) |
Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.
Biomarker eligibility criteria
- MET exon 14 skipping alterations
References
- VISIONNSCLC: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02864992
Advanced or metastatic disease, subsequent lines of therapy
Docetaxel monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Awaiting publication (M18-868) | 2022-ongoing | Phase 3 (C) | Telisotuzumab vedotin | TBD if different co-primary outcomes of PFS/OS |
References
- M18-868: NCT04928846